Schütz R M, Teufel W, Glocke M
Med Klin. 1976 Sep 24;71(39):1605-10.
A double blind cross-over study under acute experimental conditions was carried out in 26 patients with angiographically confirmed occlusion in one or two limbs in order to see whether a change in the formulation of raubasine preparations improves the circulation in diseased limbs. Either 100mg raubasine or placebo tablets were administered in a randomized order. Blood flow at rest and "peak-flow" after total arterial occlusion for 3 min showed a significant improvement under raubasine compared with the pre-occlusion period whilst these parameters were not affected by placebo. Systolic blood pressure and heart rate remained almost constant under raubasine whilst they were reduced under placebo. A similar response was seen in a subgroup of 19 patients with occlusion of the femoral artery. It can thus be said that in the present investigation the new formulation of raubasine preparation (MF 706d) has been shown in a double blind study to improve both the blood flow at rest and the "peak-flow" to a significant degree in patients with arterial occlusions.
对26例经血管造影证实一肢或两肢血管闭塞的患者进行了急性实验条件下的双盲交叉研究，以观察萝巴新制剂配方的改变是否能改善患肢的血液循环。随机给予100mg萝巴新或安慰剂片。与闭塞前相比，萝巴新治疗下静息血流和总动脉闭塞3分钟后的“峰值血流”有显著改善，而这些参数不受安慰剂影响。萝巴新治疗下收缩压和心率几乎保持不变，而安慰剂治疗下则降低。在19例股动脉闭塞患者的亚组中也观察到类似反应。因此可以说，在本研究中，萝巴新制剂的新配方（MF 706d）在双盲研究中已显示出能显著改善动脉闭塞患者的静息血流和“峰值血流”。
